Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

Delayed Data
As of Sep 27
 +0.26 / +0.47%
Today’s Change
Today|||52-Week Range
Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
Sep 27 / TheStreet.com - Paid Partner Content
Gilead to Stop GS-5745 Development for Ulcerative Colitis
Sep 22 / Zacks.com - Paid Partner Content
Dr. Lisa Bardacks Faustian Bargain
Sep 25 / Investing Channel - Paid Partner Content
Bristol-Myers Opdivo's Regulatory Application Validated in EU
Sep 21 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Sep 23 / Zacks.com - Paid Partner Content
Opinions split on Witty regime at GSK
Sep 20 / FT.com - Paid Partner Content
Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy
Sep 22 / TheStreet.com - Paid Partner Content
Bristol-Myers Squibb misses mark with cancer drug
Aug 30 / FT.com - Paid Partner Content
52-Week Company Lows
Sep 22 / GuruFocus News - Paid Partner Content